Questions Over Adjuvant Ipilimumab in Melanoma Questions Over Adjuvant Ipilimumab in Melanoma

An editorial raises questions on data for patient-reported outcomes for adjuvant ipilimumab, 10 mg/kg, in melanoma; toxicity also questioned.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news